Dermapharm Holding SE (STU:DMP) EV-to-Revenue : 2.58 (As of Jun. 22, 2024)

View and export this data going back to 2018. Start your Free Trial

What is Dermapharm Holding SE EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Dermapharm Holding SE's enterprise value is €2,873 Mil. Dermapharm Holding SE's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was €1,115 Mil. Therefore, Dermapharm Holding SE's EV-to-Revenue for today is 2.58.

The historical rank and industry rank for Dermapharm Holding SE's EV-to-Revenue or its related term are showing as below:

STU:DMP' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.42 Med: 2.98 Max: 6.08
Current: 2.58

During the past 11 years, the highest EV-to-Revenue of Dermapharm Holding SE was 6.08. The lowest was 1.42. And the median was 2.98.

STU:DMP's EV-to-Revenue is ranked worse than
55.3% of 1018 companies
in the Drug Manufacturers industry
Industry Median: 2.21 vs STU:DMP: 2.58

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-06-22), Dermapharm Holding SE's stock price is €36.00. Dermapharm Holding SE's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was €20.65. Therefore, Dermapharm Holding SE's PS Ratio for today is 1.74.

Dermapharm Holding SE EV-to-Revenue Historical Data

The historical data trend for Dermapharm Holding SE's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dermapharm Holding SE EV-to-Revenue Chart

Dermapharm Holding SE Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Get a 7-Day Free Trial

3.72

4.50

5.52

2.33

2.82

Dermapharm Holding SE Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-Revenue	Get a 7-Day Free Trial															1.60	2.98	1.70	2.82	1.52

Competitive Comparison of Dermapharm Holding SE's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Dermapharm Holding SE's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Dermapharm Holding SE's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Dermapharm Holding SE's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Dermapharm Holding SE's EV-to-Revenue falls into.

Dermapharm Holding SE EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Dermapharm Holding SE's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	2872.511	/	1114.924
	=	2.58

Dermapharm Holding SE's current Enterprise Value is €2,873 Mil.
Dermapharm Holding SE's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €1,115 Mil.

Dermapharm Holding SE (STU:DMP) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Dermapharm Holding SE's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	36.00	/	20.648
	=	1.74

Dermapharm Holding SE's share price for today is €36.00.
Dermapharm Holding SE's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €20.65.

Dermapharm Holding SE EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Dermapharm Holding SE's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Dermapharm Holding SE (STU:DMP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dermapharm Holding SE (STU:DMP) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

0A5J:UK DMP:Germany

Address

Lil-Dagover-Ring 7, Grunwald, BY, DEU, 82031

Website

https://www.dermapharm.de

Dermapharm Holding SE manufactures patent-free branded pharmaceuticals for selected therapy fields, over-the-counter drugs and natural remedies. Its portfolio of products includes cosmetics, nutritional supplements and diet and medical devices. Business operating segments include Branded pharmaceuticals and other healthcare products which drive key revenue, Herbal extracts and Parallel import business. Branded pharmaceuticals and other healthcare products focus on the development, manufacturing and marketing of branded pharmaceuticals and other healthcare products. Herbal extracts include the manufacturing of phytopharmaceuticals, nutraceuticals and cosmetics products. Parallel import brands business operates under the AxiCorp brand.

Dermapharm Holding SE (STU:DMP) Headlines

No Headlines